23andMe Cuts Back Drug Research, Moves to Weight Loss (Correct)

23andMe Holding Co.’s strategy is shifting as the struggling DNA-testing firm shuts down its in-house drug development effort and gets into weight-loss, one of the hottest markets in health care.

The Silicon Valley firm plans to launch a telehealth membership program by the end of the month for people trying to shed pounds, it said in a release Thursday. Users will be able to get brand name or compounded forms of semaglutide, the active ingredient in the blockbuster drugs from Novo Nordisk A/S, it said.

23andMe is focused on raising its stock price, to get back into regulatory ...